drugset / Trial / NCT02685605

Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme

NCT02685605

RandomizedParallel-groupOpen-labelTreatment

Summary

INTRAGO II resembles a multicentric, prospective, randomized, 2-arm, open-label clinical phase III trial which tests if the median progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of intraoperative radiotherapy (IORT) to standard radiochemotherapy.

Timeline

Start
2016-12-09
Primary completion
2025-11
Completion
2026-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule 150 mg/m2
Subject Temozolomide Small molecule 200 mg/m2

Indications